[Clostridium Difficile: Monoclonal Antibody Therapy and Vaccines]
- PMID: 31212328
- DOI: 10.1055/a-0882-7530
[Clostridium Difficile: Monoclonal Antibody Therapy and Vaccines]
Abstract
Hospital-acquired Clostridium difficile infections have become much more frequent in recent years. Besides treatment with antibiotics and fecal microbiota transplant, new preventive strategies are available now. Bezlotoxumab is an antibody against toxin B and may reduce the risk of relapse by roughly 10 %. Several vaccine candidates against toxins A and B and surface-associated antigens were immunogenic and are tested in clinical trials to investigate the efficacy and safety.
© Georg Thieme Verlag KG Stuttgart · New York.
Conflict of interest statement
ML: Prüfer bei klinischen Studien (Valneva, Pfizer, GSK, Themis Bioscience), Vortragshonorar Astellas, Janssen, Roche.ECR: Prüfer bei klinischen Studien (Valneva, Pfizer, GSK, Themis Bioscience), Vortragshonorar Roche, Infectopharm.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources